

1 **List of Highest Priority Devices for**
2 **Human Factors Review**

3
4 **Draft Guidance for Industry and**
5 **Food and Drug Administration Staff**

6
7
8 ***DRAFT GUIDANCE***
9

10 **This draft guidance document is being distributed for comment purposes only.**

11
12 **Document issued on February 3, 2016.**

13
14
15 You should submit comments and suggestions regarding this draft document within 90 days of
16 publication in the *Federal Register* of the notice announcing the availability of the draft
17 guidance. Submit electronic comments to <http://www.regulations.gov>. Submit written
18 comments to the Division of Dockets Management (HFA-305), Food and Drug Administration,
19 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Identify all comments with the docket
20 number listed in the notice of availability that publishes in the *Federal Register*.

21
22 For questions regarding this document, contact the Human Factors Premarket Evaluation Team
23 at (301) 796-5580.



**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Office of Device Evaluation**

Preface

33

34

35

Additional Copies

37

38 Additional copies are available from the Internet. You may also send an e-mail request to [CDRH-](mailto:CDRH-Guidance@fda.hhs.gov)

39 Guidance@fda.hhs.gov to receive a copy of the guidance. Please use the document number

40 1500052 to identify the guidance you are requesting.

41

DRAFT

List of Highest Priority Devices for Human Factors Review

Draft Guidance for Industry and Food and Drug Administration Staff

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

I. Introduction

FDA is issuing this guidance document in order to inform medical device manufacturers which device types should have human factors data included in premarket submissions (i.e., for PMA, 510(k)). FDA believes these device types have clear potential for serious harm resulting from use error, and that review of human factors data in premarket submissions will help FDA evaluate the safety and effectiveness and substantial equivalence of these devices.

FDA's guidance documents, including this draft guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidance means that something is suggested or recommended, but not required.

II. Background

FDA issued the guidance document, *Applying Human Factors and Usability Engineering to Medical Devices, Guidance for Industry and Food and Drug Administration Staff*, to assist industry in following appropriate human factors and usability engineering processes to maximize the likelihood that new medical devices will be safe and effective for the intended users, uses and use environments.

Contains Nonbinding Recommendations

Draft – Not for Implementation

77 For devices that should include human factors data in premarket submissions, as listed here,
78 manufacturers should provide FDA with a report (see Appendix A of *Applying Human Factors*
79 *and Usability Engineering to Medical Devices*) that summarizes the human factors or usability
80 engineering processes they have followed, including any preliminary analyses and evaluations
81 and human factors validation testing, results and conclusions.
82

III. List of Device Types for Which Human Factors Data Should be Submitted for Review

85
86 CDRH considers human factors testing a valuable component of product development for
87 medical devices. CDRH recommends that manufacturers consider human factors testing for
88 medical devices as a part of a robust design control subsystem. However, in an effort to make
89 CDRH's premarket submission expectations clear, CDRH has identified circumstances under
90 which human factors validation testing should be submitted in a premarket submission. These
91 devices noted below were selected because they have clear potential for serious harm resulting
92 from use error. This identification was based on knowledge gleaned through Medical Device
93 Reporting (MDRs) and recall information. Human factors data should be included in premarket
94 submissions for these devices unless the submission does not involve any changes to users, user
95 tasks, user interface, or use environments from those of the predicates.
96

- 97 • Ablation generators (associated with ablation systems, e.g., LPB, OAD, OAE, OCM,
98 OCL)
- 99 • Anesthesia machines (e.g., BSZ)
- 100 • Artificial pancreas systems (e.g., OZO, OZP, OZQ)
- 101 • Auto injectors (when CDRH is lead Center; e.g., KZE, KZH, NSC)
- 102 • Automated external defibrillators (e.g., MKJ, NSA)
- 103 • Duodenoscopes (on the reprocessing; e.g., FDT) with elevator channels
- 104 • Gastroenterology-urology endoscopic ultrasound systems (on the reprocessing; e.g.,
105 ODG) with elevator channels
- 106 • Hemodialysis and peritoneal dialysis systems (e.g., FKP, FKT, FKX, KDI, KPF ODX,
107 ONW)
- 108 • Implanted infusion pumps (e.g., LKK, MDY)
- 109 • Infusion pumps (e.g., FRN, LZH, MEA, MRZ)
- 110 • Insulin delivery systems (e.g., LZG, OPP)
- 111 • Negative-pressure wound therapy (e.g., OKO, OMP) intended for use in the home
- 112 • Robotic catheter manipulation systems (e.g., DXX)
- 113 • Robotic surgery devices (e.g., NAY)
- 114 • Ventilators (e.g., CBK, NOU, ONZ)
- 115 • Ventricular assist devices (e.g., DSQ, PCK)

116
117 Note that FDA may recommend or require that human factors data be included in premarket
118 submissions for additional device types though product specific guidance documents, special

Contains Nonbinding Recommendations

Draft – Not for Implementation

119 controls guidance or guideline documents, or special controls contained in medical device
120 classification regulations. Premarket reviewers may also determine that human factors data are
121 needed in specific premarket submissions on a case-by-case basis (see Section IV below).
122

123 **IV. How this List Should be Used for Premarket** 124 **Submissions**

125
126 **For device types on the list:** Any premarket submission for the device types listed above should
127 include either a human factors test report and data as described in *Applying Human Factors and*
128 *Usability Engineering to Medical Devices*
129 ([http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm259760.p](http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm259760.pdf)
130 [df](http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm259760.pdf)), or should provide a detailed rationale that supports the conclusion that human factors data are
131 not necessary. In essence, this rationale would be based on analysis of risk associated with users,
132 uses, and use environments and results of that analysis would indicate that the severity of the
133 potential harm resulting from use error is not serious.

134
135 **For device types not on the list:** Submissions for device types not on the list above should
136 contain human factors data if analysis of risk indicates that users performing tasks incorrectly or
137 failing to perform tasks could result in serious harm. ODE may also determine that human
138 factors data are needed in a specific premarket submission on a case-by-case basis when one or
139 more of the following apply:

- 140
- 141 • **Submission type:** Premarket Application (PMA) or De Novo Petition for a device that
142 has potential for serious harm resulting from use error
 - 143 • **User interface modification:** New or different user interface features were implemented
144 to satisfy a special control¹ or recommendation (in a device-specific guidance document)
145 related to its use
 - 146 • **Different users:** The submission includes a change of intended users, for instance the
147 new device is intended for use by lay users when the predicates were labeled for use only
148 by healthcare professionals and device use has potential for serious harm resulting from
149 use error
 - 150 • **Recalls, adverse events, and problem reports:** The device type has been associated
151 with recalls, adverse events, problem reports or complaints for which the cause has been
152 attributed to use error or use error is the only explanation
 - 153 • **Device modifications:** The device was modified or differs from the predicate in any of
154 the following ways and the device has potential for serious harm resulting from use error:
 - 155 ○ The user interface has been modified (even if it has been simplified)
 - 156 ○ User tasks have been added or changed
 - 157 ○ The severity of possible harm resulting from use error has increased

¹ Special controls are regulatory requirements for class II devices and are usually device specific. These controls can include premarket data requirements.

Contains Nonbinding Recommendations

Draft – Not for Implementation

158
159

- The device will be used in a new use environment (e.g., in the home or a moving vehicle)

DRAFT